Xylo Technologies Ltd.

XYLO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XYLO stands at 3.8M. In comparison, ABT has a market cap of 177.9B. Regarding current trading prices, XYLO is priced at $5.07, while ABT trades at $102.37.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XYLO currently has a P/E ratio of -0.63, whereas ABT's P/E ratio is 28.05. In terms of profitability, XYLO's ROE is +0.12%, compared to ABT's ROE of +0.13%. Regarding short-term risk, XYLO is less volatile compared to ABT. This indicates potentially lower risk in terms of short-term price fluctuations for XYLO.Check ABT's competition here

XYLO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XYLO stands at 3.8M. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, XYLO is priced at $5.07, while BSX-PA trades at $122.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XYLO currently has a P/E ratio of -0.63, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, XYLO's ROE is +0.12%, compared to BSX-PA's ROE of +0.13%. Regarding short-term risk, XYLO is less volatile compared to BSX-PA. This indicates potentially lower risk in terms of short-term price fluctuations for XYLO.Check BSX-PA's competition here

XYLO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XYLO stands at 3.8M. In comparison, SYK has a market cap of 126B. Regarding current trading prices, XYLO is priced at $5.07, while SYK trades at $329.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XYLO currently has a P/E ratio of -0.63, whereas SYK's P/E ratio is 39.16. In terms of profitability, XYLO's ROE is +0.12%, compared to SYK's ROE of +0.15%. Regarding short-term risk, XYLO is less volatile compared to SYK. This indicates potentially lower risk in terms of short-term price fluctuations for XYLO.Check SYK's competition here

XYLO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XYLO stands at 3.8M. In comparison, MDT has a market cap of 110.5B. Regarding current trading prices, XYLO is priced at $5.07, while MDT trades at $86.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XYLO currently has a P/E ratio of -0.63, whereas MDT's P/E ratio is 24.45. In terms of profitability, XYLO's ROE is +0.12%, compared to MDT's ROE of +0.10%. Regarding short-term risk, XYLO is less volatile compared to MDT. This indicates potentially lower risk in terms of short-term price fluctuations for XYLO.Check MDT's competition here

XYLO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XYLO stands at 3.8M. In comparison, BSX has a market cap of 92B. Regarding current trading prices, XYLO is priced at $5.07, while BSX trades at $62.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XYLO currently has a P/E ratio of -0.63, whereas BSX's P/E ratio is 31.96. In terms of profitability, XYLO's ROE is +0.12%, compared to BSX's ROE of +0.13%. Regarding short-term risk, XYLO is less volatile compared to BSX. This indicates potentially lower risk in terms of short-term price fluctuations for XYLO.Check BSX's competition here

XYLO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XYLO stands at 3.8M. In comparison, EW has a market cap of 47.2B. Regarding current trading prices, XYLO is priced at $5.07, while EW trades at $81.28.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XYLO currently has a P/E ratio of -0.63, whereas EW's P/E ratio is 44.91. In terms of profitability, XYLO's ROE is +0.12%, compared to EW's ROE of +0.10%. Regarding short-term risk, XYLO is less volatile compared to EW. This indicates potentially lower risk in terms of short-term price fluctuations for XYLO.Check EW's competition here

XYLO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XYLO stands at 3.8M. In comparison, BRKRP has a market cap of 43.6B. Regarding current trading prices, XYLO is priced at $5.07, while BRKRP trades at $287.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XYLO currently has a P/E ratio of -0.63, whereas BRKRP's P/E ratio is N/A. In terms of profitability, XYLO's ROE is +0.12%, compared to BRKRP's ROE of -0.00%. Regarding short-term risk, XYLO is less volatile compared to BRKRP. This indicates potentially lower risk in terms of short-term price fluctuations for XYLO.Check BRKRP's competition here

XYLO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XYLO stands at 3.8M. In comparison, PHG has a market cap of 26.2B. Regarding current trading prices, XYLO is priced at $5.07, while PHG trades at $27.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XYLO currently has a P/E ratio of -0.63, whereas PHG's P/E ratio is 25.51. In terms of profitability, XYLO's ROE is +0.12%, compared to PHG's ROE of +0.08%. Regarding short-term risk, XYLO is less volatile compared to PHG. This indicates potentially lower risk in terms of short-term price fluctuations for XYLO.Check PHG's competition here

XYLO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XYLO stands at 3.8M. In comparison, DXCM has a market cap of 24.3B. Regarding current trading prices, XYLO is priced at $5.07, while DXCM trades at $62.37.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XYLO currently has a P/E ratio of -0.63, whereas DXCM's P/E ratio is 29.84. In terms of profitability, XYLO's ROE is +0.12%, compared to DXCM's ROE of +0.32%. Regarding short-term risk, XYLO is less volatile compared to DXCM. This indicates potentially lower risk in terms of short-term price fluctuations for XYLO.Check DXCM's competition here

XYLO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XYLO stands at 3.8M. In comparison, STE has a market cap of 21.6B. Regarding current trading prices, XYLO is priced at $5.07, while STE trades at $219.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XYLO currently has a P/E ratio of -0.63, whereas STE's P/E ratio is 30.71. In terms of profitability, XYLO's ROE is +0.12%, compared to STE's ROE of +0.10%. Regarding short-term risk, XYLO is less volatile compared to STE. This indicates potentially lower risk in terms of short-term price fluctuations for XYLO.Check STE's competition here

XYLO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XYLO stands at 3.8M. In comparison, ZBH has a market cap of 18B. Regarding current trading prices, XYLO is priced at $5.07, while ZBH trades at $91.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XYLO currently has a P/E ratio of -0.63, whereas ZBH's P/E ratio is 25.65. In terms of profitability, XYLO's ROE is +0.12%, compared to ZBH's ROE of +0.06%. Regarding short-term risk, XYLO is less volatile compared to ZBH. This indicates potentially lower risk in terms of short-term price fluctuations for XYLO.Check ZBH's competition here

XYLO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XYLO stands at 3.8M. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, XYLO is priced at $5.07, while ABMD trades at $381.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XYLO currently has a P/E ratio of -0.63, whereas ABMD's P/E ratio is 65.36. In terms of profitability, XYLO's ROE is +0.12%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, XYLO is less volatile compared to ABMD. This indicates potentially lower risk in terms of short-term price fluctuations for XYLO.Check ABMD's competition here

XYLO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XYLO stands at 3.8M. In comparison, PODD has a market cap of 14.6B. Regarding current trading prices, XYLO is priced at $5.07, while PODD trades at $207.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XYLO currently has a P/E ratio of -0.63, whereas PODD's P/E ratio is 59.67. In terms of profitability, XYLO's ROE is +0.12%, compared to PODD's ROE of +0.17%. Regarding short-term risk, XYLO is less volatile compared to PODD. This indicates potentially lower risk in terms of short-term price fluctuations for XYLO.Check PODD's competition here

XYLO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XYLO stands at 3.8M. In comparison, SNN has a market cap of 13.6B. Regarding current trading prices, XYLO is priced at $5.07, while SNN trades at $32.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XYLO currently has a P/E ratio of -0.63, whereas SNN's P/E ratio is 22.44. In terms of profitability, XYLO's ROE is +0.12%, compared to SNN's ROE of +0.12%. Regarding short-term risk, XYLO is less volatile compared to SNN. This indicates potentially lower risk in terms of short-term price fluctuations for XYLO.Check SNN's competition here

XYLO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XYLO stands at 3.8M. In comparison, PEN has a market cap of 12.9B. Regarding current trading prices, XYLO is priced at $5.07, while PEN trades at $329.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XYLO currently has a P/E ratio of -0.63, whereas PEN's P/E ratio is 72.64. In terms of profitability, XYLO's ROE is +0.12%, compared to PEN's ROE of +0.13%. Regarding short-term risk, XYLO is less volatile compared to PEN. This indicates potentially lower risk in terms of short-term price fluctuations for XYLO.Check PEN's competition here

XYLO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XYLO stands at 3.8M. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, XYLO is priced at $5.07, while SWAV trades at $334.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XYLO currently has a P/E ratio of -0.63, whereas SWAV's P/E ratio is 78.76. In terms of profitability, XYLO's ROE is +0.12%, compared to SWAV's ROE of +0.25%. Regarding short-term risk, XYLO is less volatile compared to SWAV. This indicates potentially lower risk in terms of short-term price fluctuations for XYLO.Check SWAV's competition here

XYLO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XYLO stands at 3.8M. In comparison, ALGN has a market cap of 12.4B. Regarding current trading prices, XYLO is priced at $5.07, while ALGN trades at $172.73.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XYLO currently has a P/E ratio of -0.63, whereas ALGN's P/E ratio is 30.54. In terms of profitability, XYLO's ROE is +0.12%, compared to ALGN's ROE of +0.10%. Regarding short-term risk, XYLO is less volatile compared to ALGN. This indicates potentially lower risk in terms of short-term price fluctuations for XYLO.Check ALGN's competition here

XYLO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XYLO stands at 3.8M. In comparison, GMED has a market cap of 11.9B. Regarding current trading prices, XYLO is priced at $5.07, while GMED trades at $87.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XYLO currently has a P/E ratio of -0.63, whereas GMED's P/E ratio is 22.39. In terms of profitability, XYLO's ROE is +0.12%, compared to GMED's ROE of +0.12%. Regarding short-term risk, XYLO is less volatile compared to GMED. This indicates potentially lower risk in terms of short-term price fluctuations for XYLO.Check GMED's competition here

XYLO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XYLO stands at 3.8M. In comparison, BIO has a market cap of 7.5B. Regarding current trading prices, XYLO is priced at $5.07, while BIO trades at $278.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XYLO currently has a P/E ratio of -0.63, whereas BIO's P/E ratio is 9.99. In terms of profitability, XYLO's ROE is +0.12%, compared to BIO's ROE of +0.11%. Regarding short-term risk, XYLO is less volatile compared to BIO. This indicates potentially lower risk in terms of short-term price fluctuations for XYLO.Check BIO's competition here

XYLO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XYLO stands at 3.8M. In comparison, BIO-B has a market cap of 7.5B. Regarding current trading prices, XYLO is priced at $5.07, while BIO-B trades at $278.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XYLO currently has a P/E ratio of -0.63, whereas BIO-B's P/E ratio is 9.99. In terms of profitability, XYLO's ROE is +0.12%, compared to BIO-B's ROE of +0.11%. Regarding short-term risk, XYLO is less volatile compared to BIO-B. This indicates potentially lower risk in terms of short-term price fluctuations for XYLO.Check BIO-B's competition here

XYLO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XYLO stands at 3.8M. In comparison, GKOS has a market cap of 6.5B. Regarding current trading prices, XYLO is priced at $5.07, while GKOS trades at $112.62.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XYLO currently has a P/E ratio of -0.63, whereas GKOS's P/E ratio is -34.33. In terms of profitability, XYLO's ROE is +0.12%, compared to GKOS's ROE of -0.25%. Regarding short-term risk, XYLO is less volatile compared to GKOS. This indicates potentially lower risk in terms of short-term price fluctuations for XYLO.Check GKOS's competition here

XYLO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XYLO stands at 3.8M. In comparison, BRKR has a market cap of 5.5B. Regarding current trading prices, XYLO is priced at $5.07, while BRKR trades at $36.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XYLO currently has a P/E ratio of -0.63, whereas BRKR's P/E ratio is -240.53. In terms of profitability, XYLO's ROE is +0.12%, compared to BRKR's ROE of -0.00%. Regarding short-term risk, XYLO is less volatile compared to BRKR. This indicates potentially lower risk in terms of short-term price fluctuations for XYLO.Check BRKR's competition here

XYLO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XYLO stands at 3.8M. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, XYLO is priced at $5.07, while NARI trades at $79.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XYLO currently has a P/E ratio of -0.63, whereas NARI's P/E ratio is -59.24. In terms of profitability, XYLO's ROE is +0.12%, compared to NARI's ROE of -0.00%. Regarding short-term risk, XYLO is less volatile compared to NARI. This indicates potentially lower risk in terms of short-term price fluctuations for XYLO.Check NARI's competition here

XYLO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XYLO stands at 3.8M. In comparison, IRTC has a market cap of 3.8B. Regarding current trading prices, XYLO is priced at $5.07, while IRTC trades at $118.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XYLO currently has a P/E ratio of -0.63, whereas IRTC's P/E ratio is -85.05. In terms of profitability, XYLO's ROE is +0.12%, compared to IRTC's ROE of -0.38%. Regarding short-term risk, XYLO is less volatile compared to IRTC. This indicates potentially lower risk in terms of short-term price fluctuations for XYLO.Check IRTC's competition here

XYLO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XYLO stands at 3.8M. In comparison, AXNX has a market cap of 3.6B. Regarding current trading prices, XYLO is priced at $5.07, while AXNX trades at $70.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XYLO currently has a P/E ratio of -0.63, whereas AXNX's P/E ratio is -709.80. In terms of profitability, XYLO's ROE is +0.12%, compared to AXNX's ROE of -0.01%. Regarding short-term risk, XYLO and AXNX have similar daily volatility (0.00).Check AXNX's competition here

XYLO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XYLO stands at 3.8M. In comparison, LIVN has a market cap of 3.5B. Regarding current trading prices, XYLO is priced at $5.07, while LIVN trades at $64.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XYLO currently has a P/E ratio of -0.63, whereas LIVN's P/E ratio is -14.52. In terms of profitability, XYLO's ROE is +0.12%, compared to LIVN's ROE of -0.21%. Regarding short-term risk, XYLO is less volatile compared to LIVN. This indicates potentially lower risk in terms of short-term price fluctuations for XYLO.Check LIVN's competition here

XYLO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XYLO stands at 3.8M. In comparison, TMDX has a market cap of 3.4B. Regarding current trading prices, XYLO is priced at $5.07, while TMDX trades at $100.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XYLO currently has a P/E ratio of -0.63, whereas TMDX's P/E ratio is 20.62. In terms of profitability, XYLO's ROE is +0.12%, compared to TMDX's ROE of +0.54%. Regarding short-term risk, XYLO is less volatile compared to TMDX. This indicates potentially lower risk in terms of short-term price fluctuations for XYLO.Check TMDX's competition here

XYLO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XYLO stands at 3.8M. In comparison, ITGR has a market cap of 3B. Regarding current trading prices, XYLO is priced at $5.07, while ITGR trades at $86.44.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XYLO currently has a P/E ratio of -0.63, whereas ITGR's P/E ratio is 29.91. In terms of profitability, XYLO's ROE is +0.12%, compared to ITGR's ROE of +0.06%. Regarding short-term risk, XYLO is less volatile compared to ITGR. This indicates potentially lower risk in terms of short-term price fluctuations for XYLO.Check ITGR's competition here

XYLO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XYLO stands at 3.8M. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, XYLO is priced at $5.07, while NUVA trades at $39.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XYLO currently has a P/E ratio of -0.63, whereas NUVA's P/E ratio is 75.00. In terms of profitability, XYLO's ROE is +0.12%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, XYLO is less volatile compared to NUVA. This indicates potentially lower risk in terms of short-term price fluctuations for XYLO.Check NUVA's competition here

XYLO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XYLO stands at 3.8M. In comparison, AXGN has a market cap of 1.7B. Regarding current trading prices, XYLO is priced at $5.07, while AXGN trades at $33.58.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XYLO currently has a P/E ratio of -0.63, whereas AXGN's P/E ratio is -98.76. In terms of profitability, XYLO's ROE is +0.12%, compared to AXGN's ROE of -0.13%. Regarding short-term risk, XYLO is less volatile compared to AXGN. This indicates potentially lower risk in terms of short-term price fluctuations for XYLO.Check AXGN's competition here

XYLO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XYLO stands at 3.8M. In comparison, ESTA has a market cap of 1.7B. Regarding current trading prices, XYLO is priced at $5.07, while ESTA trades at $58.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XYLO currently has a P/E ratio of -0.63, whereas ESTA's P/E ratio is -34.13. In terms of profitability, XYLO's ROE is +0.12%, compared to ESTA's ROE of -2.02%. Regarding short-term risk, XYLO is less volatile compared to ESTA. This indicates potentially lower risk in terms of short-term price fluctuations for XYLO.Check ESTA's competition here

XYLO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XYLO stands at 3.8M. In comparison, ATEC has a market cap of 1.7B. Regarding current trading prices, XYLO is priced at $5.07, while ATEC trades at $11.26.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XYLO currently has a P/E ratio of -0.63, whereas ATEC's P/E ratio is -11.73. In terms of profitability, XYLO's ROE is +0.12%, compared to ATEC's ROE of -17.60%. Regarding short-term risk, XYLO is less volatile compared to ATEC. This indicates potentially lower risk in terms of short-term price fluctuations for XYLO.Check ATEC's competition here

XYLO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XYLO stands at 3.8M. In comparison, PMI has a market cap of 1.6B. Regarding current trading prices, XYLO is priced at $5.07, while PMI trades at $1.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XYLO currently has a P/E ratio of -0.63, whereas PMI's P/E ratio is -2.06. In terms of profitability, XYLO's ROE is +0.12%, compared to PMI's ROE of +2.17%. Regarding short-term risk, XYLO is less volatile compared to PMI. This indicates potentially lower risk in terms of short-term price fluctuations for XYLO.Check PMI's competition here

XYLO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XYLO stands at 3.8M. In comparison, AORT has a market cap of 1.6B. Regarding current trading prices, XYLO is priced at $5.07, while AORT trades at $34.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XYLO currently has a P/E ratio of -0.63, whereas AORT's P/E ratio is 162.76. In terms of profitability, XYLO's ROE is +0.12%, compared to AORT's ROE of +0.02%. Regarding short-term risk, XYLO is less volatile compared to AORT. This indicates potentially lower risk in terms of short-term price fluctuations for XYLO.Check AORT's competition here

XYLO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XYLO stands at 3.8M. In comparison, AHCO has a market cap of 1.6B. Regarding current trading prices, XYLO is priced at $5.07, while AHCO trades at $11.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XYLO currently has a P/E ratio of -0.63, whereas AHCO's P/E ratio is -22.81. In terms of profitability, XYLO's ROE is +0.12%, compared to AHCO's ROE of -0.05%. Regarding short-term risk, XYLO is less volatile compared to AHCO. This indicates potentially lower risk in terms of short-term price fluctuations for XYLO.Check AHCO's competition here

XYLO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XYLO stands at 3.8M. In comparison, INSP has a market cap of 1.5B. Regarding current trading prices, XYLO is priced at $5.07, while INSP trades at $53.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XYLO currently has a P/E ratio of -0.63, whereas INSP's P/E ratio is 10.99. In terms of profitability, XYLO's ROE is +0.12%, compared to INSP's ROE of +0.21%. Regarding short-term risk, XYLO is less volatile compared to INSP. This indicates potentially lower risk in terms of short-term price fluctuations for XYLO.Check INSP's competition here

XYLO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XYLO stands at 3.8M. In comparison, UFPT has a market cap of 1.5B. Regarding current trading prices, XYLO is priced at $5.07, while UFPT trades at $193.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XYLO currently has a P/E ratio of -0.63, whereas UFPT's P/E ratio is 22.17. In terms of profitability, XYLO's ROE is +0.12%, compared to UFPT's ROE of +0.17%. Regarding short-term risk, XYLO is less volatile compared to UFPT. This indicates potentially lower risk in terms of short-term price fluctuations for XYLO.Check UFPT's competition here

XYLO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XYLO stands at 3.8M. In comparison, PRCT has a market cap of 1.4B. Regarding current trading prices, XYLO is priced at $5.07, while PRCT trades at $25.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XYLO currently has a P/E ratio of -0.63, whereas PRCT's P/E ratio is -14.74. In terms of profitability, XYLO's ROE is +0.12%, compared to PRCT's ROE of -0.25%. Regarding short-term risk, XYLO is less volatile compared to PRCT. This indicates potentially lower risk in terms of short-term price fluctuations for XYLO.Check PRCT's competition here

XYLO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XYLO stands at 3.8M. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, XYLO is priced at $5.07, while HSKA trades at $119.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XYLO currently has a P/E ratio of -0.63, whereas HSKA's P/E ratio is -62.49. In terms of profitability, XYLO's ROE is +0.12%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, XYLO and HSKA have similar daily volatility (0.00).Check HSKA's competition here

XYLO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XYLO stands at 3.8M. In comparison, TNDM has a market cap of 1.3B. Regarding current trading prices, XYLO is priced at $5.07, while TNDM trades at $18.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XYLO currently has a P/E ratio of -0.63, whereas TNDM's P/E ratio is -6.19. In terms of profitability, XYLO's ROE is +0.12%, compared to TNDM's ROE of -1.42%. Regarding short-term risk, XYLO is less volatile compared to TNDM. This indicates potentially lower risk in terms of short-term price fluctuations for XYLO.Check TNDM's competition here

XYLO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XYLO stands at 3.8M. In comparison, IRMD has a market cap of 1.2B. Regarding current trading prices, XYLO is priced at $5.07, while IRMD trades at $96.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XYLO currently has a P/E ratio of -0.63, whereas IRMD's P/E ratio is 55.17. In terms of profitability, XYLO's ROE is +0.12%, compared to IRMD's ROE of +0.24%. Regarding short-term risk, XYLO is less volatile compared to IRMD. This indicates potentially lower risk in terms of short-term price fluctuations for XYLO.Check IRMD's competition here

XYLO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XYLO stands at 3.8M. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, XYLO is priced at $5.07, while SILK trades at $27.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XYLO currently has a P/E ratio of -0.63, whereas SILK's P/E ratio is -18.96. In terms of profitability, XYLO's ROE is +0.12%, compared to SILK's ROE of -0.35%. Regarding short-term risk, XYLO is less volatile compared to SILK. This indicates potentially lower risk in terms of short-term price fluctuations for XYLO.Check SILK's competition here

XYLO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XYLO stands at 3.8M. In comparison, CNMD has a market cap of 1.1B. Regarding current trading prices, XYLO is priced at $5.07, while CNMD trades at $35.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XYLO currently has a P/E ratio of -0.63, whereas CNMD's P/E ratio is 23.53. In terms of profitability, XYLO's ROE is +0.12%, compared to CNMD's ROE of +0.05%. Regarding short-term risk, XYLO is less volatile compared to CNMD. This indicates potentially lower risk in terms of short-term price fluctuations for XYLO.Check CNMD's competition here

XYLO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XYLO stands at 3.8M. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, XYLO is priced at $5.07, while FNA trades at $13.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XYLO currently has a P/E ratio of -0.63, whereas FNA's P/E ratio is -19.83. In terms of profitability, XYLO's ROE is +0.12%, compared to FNA's ROE of -0.17%. Regarding short-term risk, XYLO is less volatile compared to FNA. This indicates potentially lower risk in terms of short-term price fluctuations for XYLO.Check FNA's competition here

XYLO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XYLO stands at 3.8M. In comparison, BFLY has a market cap of 1B. Regarding current trading prices, XYLO is priced at $5.07, while BFLY trades at $4.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XYLO currently has a P/E ratio of -0.63, whereas BFLY's P/E ratio is -13.21. In terms of profitability, XYLO's ROE is +0.12%, compared to BFLY's ROE of -0.35%. Regarding short-term risk, XYLO is less volatile compared to BFLY. This indicates potentially lower risk in terms of short-term price fluctuations for XYLO.Check BFLY's competition here

XYLO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XYLO stands at 3.8M. In comparison, SSII has a market cap of 942.6M. Regarding current trading prices, XYLO is priced at $5.07, while SSII trades at $4.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XYLO currently has a P/E ratio of -0.63, whereas SSII's P/E ratio is -80.83. In terms of profitability, XYLO's ROE is +0.12%, compared to SSII's ROE of -0.30%. Regarding short-term risk, XYLO is less volatile compared to SSII. This indicates potentially lower risk in terms of short-term price fluctuations for XYLO.Check SSII's competition here

XYLO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XYLO stands at 3.8M. In comparison, LMRI has a market cap of 888.9M. Regarding current trading prices, XYLO is priced at $5.07, while LMRI trades at $9.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XYLO currently has a P/E ratio of -0.63, whereas LMRI's P/E ratio is -20.43. In terms of profitability, XYLO's ROE is +0.12%, compared to LMRI's ROE of -0.18%. Regarding short-term risk, XYLO is less volatile compared to LMRI. This indicates potentially lower risk in terms of short-term price fluctuations for XYLO.Check LMRI's competition here

XYLO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XYLO stands at 3.8M. In comparison, INMD has a market cap of 868M. Regarding current trading prices, XYLO is priced at $5.07, while INMD trades at $13.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XYLO currently has a P/E ratio of -0.63, whereas INMD's P/E ratio is 9.58. In terms of profitability, XYLO's ROE is +0.12%, compared to INMD's ROE of +0.15%. Regarding short-term risk, XYLO is less volatile compared to INMD. This indicates potentially lower risk in terms of short-term price fluctuations for XYLO.Check INMD's competition here

XYLO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XYLO stands at 3.8M. In comparison, CSII has a market cap of 844M. Regarding current trading prices, XYLO is priced at $5.07, while CSII trades at $20.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XYLO currently has a P/E ratio of -0.63, whereas CSII's P/E ratio is -20.83. In terms of profitability, XYLO's ROE is +0.12%, compared to CSII's ROE of -0.14%. Regarding short-term risk, XYLO is less volatile compared to CSII. This indicates potentially lower risk in terms of short-term price fluctuations for XYLO.Check CSII's competition here

XYLO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XYLO stands at 3.8M. In comparison, IART has a market cap of 745.9M. Regarding current trading prices, XYLO is priced at $5.07, while IART trades at $9.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XYLO currently has a P/E ratio of -0.63, whereas IART's P/E ratio is -1.42. In terms of profitability, XYLO's ROE is +0.12%, compared to IART's ROE of -0.44%. Regarding short-term risk, XYLO is less volatile compared to IART. This indicates potentially lower risk in terms of short-term price fluctuations for XYLO.Check IART's competition here

XYLO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XYLO stands at 3.8M. In comparison, CRY has a market cap of 725.1M. Regarding current trading prices, XYLO is priced at $5.07, while CRY trades at $17.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XYLO currently has a P/E ratio of -0.63, whereas CRY's P/E ratio is 425.71. In terms of profitability, XYLO's ROE is +0.12%, compared to CRY's ROE of +0.02%. Regarding short-term risk, XYLO is less volatile compared to CRY. This indicates potentially lower risk in terms of short-term price fluctuations for XYLO.Check CRY's competition here

XYLO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XYLO stands at 3.8M. In comparison, CBLL has a market cap of 696.4M. Regarding current trading prices, XYLO is priced at $5.07, while CBLL trades at $18.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XYLO currently has a P/E ratio of -0.63, whereas CBLL's P/E ratio is -12.67. In terms of profitability, XYLO's ROE is +0.12%, compared to CBLL's ROE of -0.32%. Regarding short-term risk, XYLO is less volatile compared to CBLL. This indicates potentially lower risk in terms of short-term price fluctuations for XYLO.Check CBLL's competition here

XYLO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XYLO stands at 3.8M. In comparison, AVNS has a market cap of 654.8M. Regarding current trading prices, XYLO is priced at $5.07, while AVNS trades at $14.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XYLO currently has a P/E ratio of -0.63, whereas AVNS's P/E ratio is -8.97. In terms of profitability, XYLO's ROE is +0.12%, compared to AVNS's ROE of -0.09%. Regarding short-term risk, XYLO is less volatile compared to AVNS. This indicates potentially lower risk in terms of short-term price fluctuations for XYLO.Check AVNS's competition here

XYLO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XYLO stands at 3.8M. In comparison, BVS has a market cap of 616.4M. Regarding current trading prices, XYLO is priced at $5.07, while BVS trades at $9.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XYLO currently has a P/E ratio of -0.63, whereas BVS's P/E ratio is 27.73. In terms of profitability, XYLO's ROE is +0.12%, compared to BVS's ROE of +0.14%. Regarding short-term risk, XYLO is less volatile compared to BVS. This indicates potentially lower risk in terms of short-term price fluctuations for XYLO.Check BVS's competition here

XYLO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XYLO stands at 3.8M. In comparison, SRDX has a market cap of 614.5M. Regarding current trading prices, XYLO is priced at $5.07, while SRDX trades at $42.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XYLO currently has a P/E ratio of -0.63, whereas SRDX's P/E ratio is -34.66. In terms of profitability, XYLO's ROE is +0.12%, compared to SRDX's ROE of -0.16%. Regarding short-term risk, XYLO and SRDX have similar daily volatility (0.00).Check SRDX's competition here

XYLO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XYLO stands at 3.8M. In comparison, TCMD has a market cap of 590.8M. Regarding current trading prices, XYLO is priced at $5.07, while TCMD trades at $25.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XYLO currently has a P/E ratio of -0.63, whereas TCMD's P/E ratio is 31.67. In terms of profitability, XYLO's ROE is +0.12%, compared to TCMD's ROE of +0.09%. Regarding short-term risk, XYLO is less volatile compared to TCMD. This indicates potentially lower risk in terms of short-term price fluctuations for XYLO.Check TCMD's competition here

XYLO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XYLO stands at 3.8M. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, XYLO is priced at $5.07, while APEN trades at $10.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XYLO currently has a P/E ratio of -0.63, whereas APEN's P/E ratio is -9.43. In terms of profitability, XYLO's ROE is +0.12%, compared to APEN's ROE of -0.85%. Regarding short-term risk, XYLO is less volatile compared to APEN. This indicates potentially lower risk in terms of short-term price fluctuations for XYLO.Check APEN's competition here

XYLO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XYLO stands at 3.8M. In comparison, CTKB has a market cap of 575.9M. Regarding current trading prices, XYLO is priced at $5.07, while CTKB trades at $4.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XYLO currently has a P/E ratio of -0.63, whereas CTKB's P/E ratio is -8.62. In terms of profitability, XYLO's ROE is +0.12%, compared to CTKB's ROE of -0.18%. Regarding short-term risk, XYLO is less volatile compared to CTKB. This indicates potentially lower risk in terms of short-term price fluctuations for XYLO.Check CTKB's competition here

XYLO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XYLO stands at 3.8M. In comparison, SIBN has a market cap of 574.6M. Regarding current trading prices, XYLO is priced at $5.07, while SIBN trades at $13.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XYLO currently has a P/E ratio of -0.63, whereas SIBN's P/E ratio is -29.57. In terms of profitability, XYLO's ROE is +0.12%, compared to SIBN's ROE of -0.11%. Regarding short-term risk, XYLO is less volatile compared to SIBN. This indicates potentially lower risk in terms of short-term price fluctuations for XYLO.Check SIBN's competition here

XYLO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XYLO stands at 3.8M. In comparison, ZIMV has a market cap of 535.6M. Regarding current trading prices, XYLO is priced at $5.07, while ZIMV trades at $18.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XYLO currently has a P/E ratio of -0.63, whereas ZIMV's P/E ratio is -27.52. In terms of profitability, XYLO's ROE is +0.12%, compared to ZIMV's ROE of -0.05%. Regarding short-term risk, XYLO and ZIMV have similar daily volatility (0.00).Check ZIMV's competition here

XYLO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XYLO stands at 3.8M. In comparison, BWAY has a market cap of 532.6M. Regarding current trading prices, XYLO is priced at $5.07, while BWAY trades at $13.58.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XYLO currently has a P/E ratio of -0.63, whereas BWAY's P/E ratio is 75.44. In terms of profitability, XYLO's ROE is +0.12%, compared to BWAY's ROE of +0.11%. Regarding short-term risk, XYLO is less volatile compared to BWAY. This indicates potentially lower risk in terms of short-term price fluctuations for XYLO.Check BWAY's competition here

XYLO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XYLO stands at 3.8M. In comparison, NPCE has a market cap of 473.7M. Regarding current trading prices, XYLO is priced at $5.07, while NPCE trades at $14.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XYLO currently has a P/E ratio of -0.63, whereas NPCE's P/E ratio is -21.32. In terms of profitability, XYLO's ROE is +0.12%, compared to NPCE's ROE of -1.06%. Regarding short-term risk, XYLO is less volatile compared to NPCE. This indicates potentially lower risk in terms of short-term price fluctuations for XYLO.Check NPCE's competition here

XYLO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XYLO stands at 3.8M. In comparison, OFIX has a market cap of 466.1M. Regarding current trading prices, XYLO is priced at $5.07, while OFIX trades at $11.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XYLO currently has a P/E ratio of -0.63, whereas OFIX's P/E ratio is -4.98. In terms of profitability, XYLO's ROE is +0.12%, compared to OFIX's ROE of -0.20%. Regarding short-term risk, XYLO is less volatile compared to OFIX. This indicates potentially lower risk in terms of short-term price fluctuations for XYLO.Check OFIX's competition here

XYLO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XYLO stands at 3.8M. In comparison, VREX has a market cap of 445.2M. Regarding current trading prices, XYLO is priced at $5.07, while VREX trades at $10.62.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XYLO currently has a P/E ratio of -0.63, whereas VREX's P/E ratio is -6.48. In terms of profitability, XYLO's ROE is +0.12%, compared to VREX's ROE of -0.14%. Regarding short-term risk, XYLO is less volatile compared to VREX. This indicates potentially lower risk in terms of short-term price fluctuations for XYLO.Check VREX's competition here

XYLO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XYLO stands at 3.8M. In comparison, KIDS has a market cap of 411.8M. Regarding current trading prices, XYLO is priced at $5.07, while KIDS trades at $16.29.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XYLO currently has a P/E ratio of -0.63, whereas KIDS's P/E ratio is -9.64. In terms of profitability, XYLO's ROE is +0.12%, compared to KIDS's ROE of -0.11%. Regarding short-term risk, XYLO is less volatile compared to KIDS. This indicates potentially lower risk in terms of short-term price fluctuations for XYLO.Check KIDS's competition here

XYLO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XYLO stands at 3.8M. In comparison, PACB has a market cap of 407.7M. Regarding current trading prices, XYLO is priced at $5.07, while PACB trades at $1.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XYLO currently has a P/E ratio of -0.63, whereas PACB's P/E ratio is -0.74. In terms of profitability, XYLO's ROE is +0.12%, compared to PACB's ROE of -11.23%. Regarding short-term risk, XYLO is less volatile compared to PACB. This indicates potentially lower risk in terms of short-term price fluctuations for XYLO.Check PACB's competition here

XYLO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XYLO stands at 3.8M. In comparison, VMD has a market cap of 370.2M. Regarding current trading prices, XYLO is priced at $5.07, while VMD trades at $9.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XYLO currently has a P/E ratio of -0.63, whereas VMD's P/E ratio is 25.92. In terms of profitability, XYLO's ROE is +0.12%, compared to VMD's ROE of +0.11%. Regarding short-term risk, XYLO is less volatile compared to VMD. This indicates potentially lower risk in terms of short-term price fluctuations for XYLO.Check VMD's competition here

XYLO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XYLO stands at 3.8M. In comparison, CERS has a market cap of 359.4M. Regarding current trading prices, XYLO is priced at $5.07, while CERS trades at $1.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XYLO currently has a P/E ratio of -0.63, whereas CERS's P/E ratio is -23.37. In terms of profitability, XYLO's ROE is +0.12%, compared to CERS's ROE of -0.26%. Regarding short-term risk, XYLO is less volatile compared to CERS. This indicates potentially lower risk in terms of short-term price fluctuations for XYLO.Check CERS's competition here

XYLO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XYLO stands at 3.8M. In comparison, LAB has a market cap of 358.2M. Regarding current trading prices, XYLO is priced at $5.07, while LAB trades at $0.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XYLO currently has a P/E ratio of -0.63, whereas LAB's P/E ratio is -6.12. In terms of profitability, XYLO's ROE is +0.12%, compared to LAB's ROE of -0.18%. Regarding short-term risk, XYLO is less volatile compared to LAB. This indicates potentially lower risk in terms of short-term price fluctuations for XYLO.Check LAB's competition here

XYLO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XYLO stands at 3.8M. In comparison, DCTH has a market cap of 331.5M. Regarding current trading prices, XYLO is priced at $5.07, while DCTH trades at $9.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XYLO currently has a P/E ratio of -0.63, whereas DCTH's P/E ratio is 136.29. In terms of profitability, XYLO's ROE is +0.12%, compared to DCTH's ROE of +0.03%. Regarding short-term risk, XYLO is less volatile compared to DCTH. This indicates potentially lower risk in terms of short-term price fluctuations for XYLO.Check DCTH's competition here

XYLO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XYLO stands at 3.8M. In comparison, CATX has a market cap of 322.4M. Regarding current trading prices, XYLO is priced at $5.07, while CATX trades at $4.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XYLO currently has a P/E ratio of -0.63, whereas CATX's P/E ratio is -3.10. In terms of profitability, XYLO's ROE is +0.12%, compared to CATX's ROE of -0.41%. Regarding short-term risk, XYLO is less volatile compared to CATX. This indicates potentially lower risk in terms of short-term price fluctuations for XYLO.Check CATX's competition here

XYLO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XYLO stands at 3.8M. In comparison, SMLR has a market cap of 310.7M. Regarding current trading prices, XYLO is priced at $5.07, while SMLR trades at $20.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XYLO currently has a P/E ratio of -0.63, whereas SMLR's P/E ratio is 3.92. In terms of profitability, XYLO's ROE is +0.12%, compared to SMLR's ROE of +0.16%. Regarding short-term risk, XYLO and SMLR have similar daily volatility (0.00).Check SMLR's competition here

XYLO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XYLO stands at 3.8M. In comparison, SENS has a market cap of 277.8M. Regarding current trading prices, XYLO is priced at $5.07, while SENS trades at $6.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XYLO currently has a P/E ratio of -0.63, whereas SENS's P/E ratio is -4.01. In terms of profitability, XYLO's ROE is +0.12%, compared to SENS's ROE of -1.04%. Regarding short-term risk, XYLO is less volatile compared to SENS. This indicates potentially lower risk in terms of short-term price fluctuations for XYLO.Check SENS's competition here

XYLO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XYLO stands at 3.8M. In comparison, CLPT has a market cap of 271.9M. Regarding current trading prices, XYLO is priced at $5.07, while CLPT trades at $9.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XYLO currently has a P/E ratio of -0.63, whereas CLPT's P/E ratio is -10.16. In terms of profitability, XYLO's ROE is +0.12%, compared to CLPT's ROE of -1.22%. Regarding short-term risk, XYLO is less volatile compared to CLPT. This indicates potentially lower risk in terms of short-term price fluctuations for XYLO.Check CLPT's competition here

XYLO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XYLO stands at 3.8M. In comparison, RXST has a market cap of 261.6M. Regarding current trading prices, XYLO is priced at $5.07, while RXST trades at $6.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XYLO currently has a P/E ratio of -0.63, whereas RXST's P/E ratio is -6.67. In terms of profitability, XYLO's ROE is +0.12%, compared to RXST's ROE of -0.14%. Regarding short-term risk, XYLO is less volatile compared to RXST. This indicates potentially lower risk in terms of short-term price fluctuations for XYLO.Check RXST's competition here

XYLO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XYLO stands at 3.8M. In comparison, MGRM has a market cap of 243.8M. Regarding current trading prices, XYLO is priced at $5.07, while MGRM trades at $6.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XYLO currently has a P/E ratio of -0.63, whereas MGRM's P/E ratio is -11.11. In terms of profitability, XYLO's ROE is +0.12%, compared to MGRM's ROE of -1.37%. Regarding short-term risk, XYLO and MGRM have similar daily volatility (0.00).Check MGRM's competition here

XYLO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XYLO stands at 3.8M. In comparison, CVRX has a market cap of 239.4M. Regarding current trading prices, XYLO is priced at $5.07, while CVRX trades at $9.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XYLO currently has a P/E ratio of -0.63, whereas CVRX's P/E ratio is -4.46. In terms of profitability, XYLO's ROE is +0.12%, compared to CVRX's ROE of -0.99%. Regarding short-term risk, XYLO is less volatile compared to CVRX. This indicates potentially lower risk in terms of short-term price fluctuations for XYLO.Check CVRX's competition here

XYLO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XYLO stands at 3.8M. In comparison, MASS has a market cap of 232.1M. Regarding current trading prices, XYLO is priced at $5.07, while MASS trades at $6.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XYLO currently has a P/E ratio of -0.63, whereas MASS's P/E ratio is -6.68. In terms of profitability, XYLO's ROE is +0.12%, compared to MASS's ROE of +0.13%. Regarding short-term risk, XYLO is less volatile compared to MASS. This indicates potentially lower risk in terms of short-term price fluctuations for XYLO.Check MASS's competition here

XYLO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XYLO stands at 3.8M. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, XYLO is priced at $5.07, while NVRO trades at $5.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XYLO currently has a P/E ratio of -0.63, whereas NVRO's P/E ratio is -1.91. In terms of profitability, XYLO's ROE is +0.12%, compared to NVRO's ROE of -0.27%. Regarding short-term risk, XYLO is less volatile compared to NVRO. This indicates potentially lower risk in terms of short-term price fluctuations for XYLO.Check NVRO's competition here

XYLO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XYLO stands at 3.8M. In comparison, ANIK has a market cap of 216M. Regarding current trading prices, XYLO is priced at $5.07, while ANIK trades at $14.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XYLO currently has a P/E ratio of -0.63, whereas ANIK's P/E ratio is -21.40. In terms of profitability, XYLO's ROE is +0.12%, compared to ANIK's ROE of -0.07%. Regarding short-term risk, XYLO is less volatile compared to ANIK. This indicates potentially lower risk in terms of short-term price fluctuations for XYLO.Check ANIK's competition here

XYLO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XYLO stands at 3.8M. In comparison, EYES has a market cap of 210M. Regarding current trading prices, XYLO is priced at $5.07, while EYES trades at $4.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XYLO currently has a P/E ratio of -0.63, whereas EYES's P/E ratio is N/A. In terms of profitability, XYLO's ROE is +0.12%, compared to EYES's ROE of -3.17%. Regarding short-term risk, XYLO is less volatile compared to EYES. This indicates potentially lower risk in terms of short-term price fluctuations for XYLO.Check EYES's competition here

XYLO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XYLO stands at 3.8M. In comparison, ELMD has a market cap of 197.7M. Regarding current trading prices, XYLO is priced at $5.07, while ELMD trades at $23.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XYLO currently has a P/E ratio of -0.63, whereas ELMD's P/E ratio is 23.01. In terms of profitability, XYLO's ROE is +0.12%, compared to ELMD's ROE of +0.20%. Regarding short-term risk, XYLO is less volatile compared to ELMD. This indicates potentially lower risk in terms of short-term price fluctuations for XYLO.Check ELMD's competition here

XYLO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XYLO stands at 3.8M. In comparison, SGHT has a market cap of 197.7M. Regarding current trading prices, XYLO is priced at $5.07, while SGHT trades at $3.66.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XYLO currently has a P/E ratio of -0.63, whereas SGHT's P/E ratio is -4.95. In terms of profitability, XYLO's ROE is +0.12%, compared to SGHT's ROE of -0.56%. Regarding short-term risk, XYLO is less volatile compared to SGHT. This indicates potentially lower risk in terms of short-term price fluctuations for XYLO.Check SGHT's competition here

XYLO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XYLO stands at 3.8M. In comparison, PROF has a market cap of 197.6M. Regarding current trading prices, XYLO is priced at $5.07, while PROF trades at $6.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XYLO currently has a P/E ratio of -0.63, whereas PROF's P/E ratio is -4.63. In terms of profitability, XYLO's ROE is +0.12%, compared to PROF's ROE of -0.80%. Regarding short-term risk, XYLO is less volatile compared to PROF. This indicates potentially lower risk in terms of short-term price fluctuations for XYLO.Check PROF's competition here

XYLO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XYLO stands at 3.8M. In comparison, AVR has a market cap of 195.7M. Regarding current trading prices, XYLO is priced at $5.07, while AVR trades at $5.32.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XYLO currently has a P/E ratio of -0.63, whereas AVR's P/E ratio is -2.09. In terms of profitability, XYLO's ROE is +0.12%, compared to AVR's ROE of -5.28%. Regarding short-term risk, XYLO is less volatile compared to AVR. This indicates potentially lower risk in terms of short-term price fluctuations for XYLO.Check AVR's competition here

XYLO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XYLO stands at 3.8M. In comparison, BSGM has a market cap of 191.1M. Regarding current trading prices, XYLO is priced at $5.07, while BSGM trades at $6.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XYLO currently has a P/E ratio of -0.63, whereas BSGM's P/E ratio is -5.81. In terms of profitability, XYLO's ROE is +0.12%, compared to BSGM's ROE of +17.60%. Regarding short-term risk, XYLO is less volatile compared to BSGM. This indicates potentially lower risk in terms of short-term price fluctuations for XYLO.Check BSGM's competition here

XYLO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XYLO stands at 3.8M. In comparison, MDGS has a market cap of 178.9M. Regarding current trading prices, XYLO is priced at $5.07, while MDGS trades at $2.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XYLO currently has a P/E ratio of -0.63, whereas MDGS's P/E ratio is -0.27. In terms of profitability, XYLO's ROE is +0.12%, compared to MDGS's ROE of -0.51%. Regarding short-term risk, XYLO is less volatile compared to MDGS. This indicates potentially lower risk in terms of short-term price fluctuations for XYLO.Check MDGS's competition here

XYLO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XYLO stands at 3.8M. In comparison, INGN has a market cap of 170.7M. Regarding current trading prices, XYLO is priced at $5.07, while INGN trades at $6.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XYLO currently has a P/E ratio of -0.63, whereas INGN's P/E ratio is -7.29. In terms of profitability, XYLO's ROE is +0.12%, compared to INGN's ROE of -0.12%. Regarding short-term risk, XYLO is less volatile compared to INGN. This indicates potentially lower risk in terms of short-term price fluctuations for XYLO.Check INGN's competition here

XYLO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XYLO stands at 3.8M. In comparison, QTI has a market cap of 163.9M. Regarding current trading prices, XYLO is priced at $5.07, while QTI trades at $6.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XYLO currently has a P/E ratio of -0.63, whereas QTI's P/E ratio is -3.00. In terms of profitability, XYLO's ROE is +0.12%, compared to QTI's ROE of +3.64%. Regarding short-term risk, XYLO is less volatile compared to QTI. This indicates potentially lower risk in terms of short-term price fluctuations for XYLO.Check QTI's competition here

XYLO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XYLO stands at 3.8M. In comparison, QTRX has a market cap of 163.4M. Regarding current trading prices, XYLO is priced at $5.07, while QTRX trades at $3.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XYLO currently has a P/E ratio of -0.63, whereas QTRX's P/E ratio is -1.39. In terms of profitability, XYLO's ROE is +0.12%, compared to QTRX's ROE of -0.35%. Regarding short-term risk, XYLO is less volatile compared to QTRX. This indicates potentially lower risk in terms of short-term price fluctuations for XYLO.Check QTRX's competition here

XYLO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XYLO stands at 3.8M. In comparison, QIPT has a market cap of 162.3M. Regarding current trading prices, XYLO is priced at $5.07, while QIPT trades at $3.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XYLO currently has a P/E ratio of -0.63, whereas QIPT's P/E ratio is -15.87. In terms of profitability, XYLO's ROE is +0.12%, compared to QIPT's ROE of -0.10%. Regarding short-term risk, XYLO and QIPT have similar daily volatility (0.00).Check QIPT's competition here

XYLO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XYLO stands at 3.8M. In comparison, TLSI has a market cap of 158.5M. Regarding current trading prices, XYLO is priced at $5.07, while TLSI trades at $4.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XYLO currently has a P/E ratio of -0.63, whereas TLSI's P/E ratio is -2.27. In terms of profitability, XYLO's ROE is +0.12%, compared to TLSI's ROE of +1.37%. Regarding short-term risk, XYLO is less volatile compared to TLSI. This indicates potentially lower risk in terms of short-term price fluctuations for XYLO.Check TLSI's competition here

XYLO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XYLO stands at 3.8M. In comparison, NNOX has a market cap of 153.7M. Regarding current trading prices, XYLO is priced at $5.07, while NNOX trades at $2.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XYLO currently has a P/E ratio of -0.63, whereas NNOX's P/E ratio is -2.74. In terms of profitability, XYLO's ROE is +0.12%, compared to NNOX's ROE of -0.32%. Regarding short-term risk, XYLO is less volatile compared to NNOX. This indicates potentially lower risk in terms of short-term price fluctuations for XYLO.Check NNOX's competition here

XYLO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XYLO stands at 3.8M. In comparison, APYX has a market cap of 151.8M. Regarding current trading prices, XYLO is priced at $5.07, while APYX trades at $3.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XYLO currently has a P/E ratio of -0.63, whereas APYX's P/E ratio is -13.44. In terms of profitability, XYLO's ROE is +0.12%, compared to APYX's ROE of -1.18%. Regarding short-term risk, XYLO is less volatile compared to APYX. This indicates potentially lower risk in terms of short-term price fluctuations for XYLO.Check APYX's competition here

XYLO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XYLO stands at 3.8M. In comparison, SNWV has a market cap of 144.8M. Regarding current trading prices, XYLO is priced at $5.07, while SNWV trades at $16.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XYLO currently has a P/E ratio of -0.63, whereas SNWV's P/E ratio is 41.10. In terms of profitability, XYLO's ROE is +0.12%, compared to SNWV's ROE of -1.42%. Regarding short-term risk, XYLO is less volatile compared to SNWV. This indicates potentially lower risk in terms of short-term price fluctuations for XYLO.Check SNWV's competition here

XYLO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XYLO stands at 3.8M. In comparison, EDAP has a market cap of 132.3M. Regarding current trading prices, XYLO is priced at $5.07, while EDAP trades at $3.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XYLO currently has a P/E ratio of -0.63, whereas EDAP's P/E ratio is -4.53. In terms of profitability, XYLO's ROE is +0.12%, compared to EDAP's ROE of -1.01%. Regarding short-term risk, XYLO is less volatile compared to EDAP. This indicates potentially lower risk in terms of short-term price fluctuations for XYLO.Check EDAP's competition here

XYLO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XYLO stands at 3.8M. In comparison, LUCD has a market cap of 117.6M. Regarding current trading prices, XYLO is priced at $5.07, while LUCD trades at $1.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XYLO currently has a P/E ratio of -0.63, whereas LUCD's P/E ratio is -1.67. In terms of profitability, XYLO's ROE is +0.12%, compared to LUCD's ROE of -25.74%. Regarding short-term risk, XYLO is less volatile compared to LUCD. This indicates potentially lower risk in terms of short-term price fluctuations for XYLO.Check LUCD's competition here

XYLO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XYLO stands at 3.8M. In comparison, FONR has a market cap of 114.7M. Regarding current trading prices, XYLO is priced at $5.07, while FONR trades at $18.58.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XYLO currently has a P/E ratio of -0.63, whereas FONR's P/E ratio is 16.16. In terms of profitability, XYLO's ROE is +0.12%, compared to FONR's ROE of +0.04%. Regarding short-term risk, XYLO is less volatile compared to FONR. This indicates potentially lower risk in terms of short-term price fluctuations for XYLO.Check FONR's competition here

XYLO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, XYLO stands at 3.8M. In comparison, ICAD has a market cap of 106.3M. Regarding current trading prices, XYLO is priced at $5.07, while ICAD trades at $3.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

XYLO currently has a P/E ratio of -0.63, whereas ICAD's P/E ratio is -20.37. In terms of profitability, XYLO's ROE is +0.12%, compared to ICAD's ROE of -0.12%. Regarding short-term risk, XYLO and ICAD have similar daily volatility (0.00).Check ICAD's competition here